All In Biotech

Drug Trial Radar · NCT04964986

Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)

A Multicenter, Open-label, Metabolic Balance Study to Evaluate the Effects of Apraglutide on Intestinal Absorption in Adult Subjects With Short Bowel Syndrome, Intestinal Failure (SBS-IF), and Colon-in-Continuity (CIC)

Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Jun 14, 2021

Primary completion

Jun 6, 2023

Study completion Jun 6, 2023

Sponsor

Lead sponsor
VectivBio AGIndustry
Sponsor type
Industry
First posted
Jul 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.

Conditions

  • Short Bowel Syndrome

Interventions

  • ApraglutideDrug

    Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)Time frame: Day 1 up to approximately 55 weeks
  2. Absolute Change in Absorption of Energy Over Metabolic Balance (MB) Periods From Baseline at Week 48Time frame: Baseline and Week 48

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • UZ Leuven

    Leuven, Belgium

  • Beaujon Hospital

    Clichy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.